*Some titles are tentative. Speakers and titles are subject to change.
| July 16, 2013 |
|
Session
|
Topic
|
Speaker
|
Company
|
Time
|
|
REGISTRATION & Continental Breakfast
|
|
|
7:30 - 8:30
|
|
|
Conference Opening
|
Wilson Shou
|
Bristol-Myers Squibb
|
8:30 - 8:40
|
|
Opening Plenary
|
ADME high-throughput screening has come of age, but now what?
|
David Rodrigues
|
Bristol-Myers Squibb
|
8:40 - 9:25
|
|
SESSION I: Transporters
Session Chair: Maria Fitzgerald, Genzyme
|
|
Session I Introduction |
Maria Fitzgerald |
Sanofi
|
9:25 - 9:35
|
|
Utilizing OATP1B1 HT-Transporter Assays in Drug Discovery
|
Dallas Bednarczyk
|
Novartis
|
9:35 - 10:00
|
|
The current state of QSAR models and IVIVE of hepatobiliary transport
|
Manthena Varma
|
Pfizer
|
10:00 - 10:25
|
|
BREAK
|
10:25 - 10:40
|
|
Utility of P-gp Assay in CNS Discovery
|
Caroline Lee
|
QPS LLC
|
10:40 - 11:05
|
|
Leveraging High-Throughput Mass Spectrometry-Based Transporter Assays to Drive Decision Making and Enhance ADMET Knowledge
|
Lisa Elkin
|
BMS
|
11:05 - 11:30
|
|
Vendor Presentation
|
Predicting Drug-Transporter Interaction with Caco-2 Transporter Knockout Assay Ready Plates
|
Paul Brooks
|
Sigma
|
11:30 - 12:00
|
|
Complimentary Lunch
|
|
|
|
12:00 - 1:00
|
|
SESSION II: Technology Enabling HT-ADME
Session Chair: Wilson Shou, BMS
|
|
Session II Introduction
|
Wilson Shou
|
BMS
|
1:00 - 1:10
|
|
Losing the Matrix in MALDI. Applications of LDI-MS in High Throughput Screening Supporting Drug Discovery
|
Dieter Drexler
|
BMS
|
1:10 - 1:35
|
|
High throughput metabolite ID: are we there yet?
|
Natasha Penner
|
Biogen Idec
|
1:35 - 2:00
|
|
Differential Mobility Spectrometry as a Measure of Physiocochemical Properties Related to In Vitro Absorbtion (Permeability, Solubility, and Lipophilicity)
|
John S. Janiszewski
|
Pfizer
|
2:00 - 2:25
|
|
Hepatic Artificial Tissue Constructs Affording Inter-Species Comparison of DMPK Endpoints in Human, Rat and Dog
|
Leslie Benet
|
UCSF |
2:25 - 2:50
|
|
Break
|
|
|
|
2:50 - 3:05
|
|
SESSION III: High-Throughput DDI
Session Chair: Ragu Ramanathan, QPS
|
|
|
Session IV Introduction
|
Ragu Ramanathan
|
QPS LLC
|
3:05 - 3:15
|
|
High throughput screening assays for CYP3A4 inhibition, induction, and metabolism-dependent hepatotoxicity in primary cultured human hepatocyte
|
Albert Li
|
AP Sciences Inc.
|
3:15 - 3:40
|
|
The PXR Transactivation Assay: Screening for CYP3A4 Enzyme Induction
|
Michael Sinz |
BMS |
3:40 - 4:05
|
|
Trials and Tribulations in Development and Application of Higher Throughput Methods for Time-Dependent Inhibition (TDI) of CYP3A
|
Sharon Ripp
|
Pfizer
|
4:05 - 4:30
|
|
Ending Plenary
|
Application of HT-ADME data in candidate optimization- Pfizer case studies
|
Amit Kelagutkar
|
Pfizer
|
4:30 - 5:15
|
|
Evening Reception Sponsored by
|
5:15 - 6:15
|
|
|
|
